Current status of the development of trans-platinum antitumor drugs.
about
cis -Diammine(pyridine)chloroplatinum(II), a monofunctional platinum(II) antitumor agent: Uptake, structure, function, and prospectsThe Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) ProdrugsSynthesis, characterization and biological activity of trans-platinum(II) and trans-platinum(IV) complexes with 4-hydroxymethylpyridine.Nutlin-3 protects kidney cells during cisplatin therapy by suppressing Bax/Bak activation.Binding studies of a novel antitumor palladium(II) complex to calf thymus DNA.Arene-Ru(II)-chloroquine complexes interact with DNA, induce apoptosis on human lymphoid cell lines and display low toxicity to normal mammalian cells.Unusual DNA binding modes for metal anticancer complexes.Bis-picolinamide Ruthenium(III) Dihalide Complexes: Dichloride-to-Diiodide Exchange Generates Single trans Isomers with High Potency and Cancer Cell Selectivity.Inhibition of transcription by platinum antitumor compoundsProteins as possible targets for cytotoxic trans-platinum(II) complexes with aliphatic amine ligands: Further exceptions to the DNA paradigm.DNA-protein cross-linking by trans-[PtCl(2)(E-iminoether)(2)]. A concept for activation of the trans geometry in platinum antitumor complexesThe induction of lysis in lysogenic strains of Escherichia coli by a new antitumor transplatin derivative and its DNA interactions.N6-benzyladenosine derivatives as novel N-donor ligands of platinum(II) dichlorido complexes.Cytotoxic Profile and Peculiar Reactivity with Biomolecules of a Novel "Rule-Breaker" Iodidoplatinum(II) Complex.Cellular accumulation and DNA interaction studies of cytotoxic trans-platinum anticancer compounds.Apoptosis induction and DNA interstrand cross-link formation by cytotoxic trans-[PtCl2(NH(CH3)2)(NHCH(CH3)2) : cross-linking between d(G) and complementary d(C) within oligonucleotide duplexes.Geometry matters: inverse cytotoxic relationship for cis/trans-Ru(ii) polypyridyl complexes from cis/trans-[PtCl2(NH3)2]Activation of trans geometry in bifunctional mononuclear platinum complexes by a piperidine ligand. Mechanistic studies on antitumor action.Synthesis, characterisation and in vitro cytotoxicity of mixed ligand Pt(ii) oxadiazoline complexes with hexamethylenetetramine and 7-nitro-1,3,5-triazaadamantane.Deciphering of interactions between platinated DNA and HMGB1 by hydrogen/deuterium exchange mass spectrometry.
P2860
Q27650949-984E6726-C201-4495-952D-B6C3E8472BB5Q28066801-B8567114-1743-478C-B147-CDBFCBFCF4BEQ31011200-5F369C63-EB38-4B7A-84E6-708F61222B48Q33808489-DE1B964F-C572-4AFC-83AD-DE528C7F47DAQ33968764-A932D4A8-38DA-4312-AD3B-0E41A3A27E12Q34020456-B4183614-E153-4010-BA70-F98E249D101FQ34071185-41F0787E-2DEF-4D1A-933E-419230194E82Q36287265-A28D2A3B-4DDE-4E7A-A3D9-031F5C6D08EFQ37364815-7AA98651-0023-4D3F-9A0D-889F2804C50CQ37576021-7F47A9DC-D62A-4568-AA7B-9914C2C53128Q38348382-FBE44B97-DF9F-424A-8560-1CE324520E39Q38939537-73BF5D06-CD59-4B8F-809E-74A7EC097215Q39138998-2E2324B5-6327-4FD0-B8AA-451A56EBEE19Q39155790-E3215AB2-251B-4089-8C3A-5D8FCB8FD5ECQ39415554-3657E0F5-84F8-432D-85AC-81C681A4545CQ40115562-AF5C05FD-0BE1-428A-B543-F5352453B1AAQ42161331-3DD46D0A-D310-4311-BAFC-2FA36E59424DQ44582569-64CA4326-F2ED-4AC4-88AD-75006BAD0C6EQ47898908-3C0B0EFD-9AAE-4347-992A-E7982F712DB3Q51045898-6BADA2EB-5A13-4895-AF0D-3862EC83C535
P2860
Current status of the development of trans-platinum antitumor drugs.
description
2000 nî lūn-bûn
@nan
2000 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
Current status of the development of trans-platinum antitumor drugs.
@ast
Current status of the development of trans-platinum antitumor drugs.
@en
type
label
Current status of the development of trans-platinum antitumor drugs.
@ast
Current status of the development of trans-platinum antitumor drugs.
@en
prefLabel
Current status of the development of trans-platinum antitumor drugs.
@ast
Current status of the development of trans-platinum antitumor drugs.
@en
P2093
P1476
Current status of the development of trans-platinum antitumor drugs.
@en
P2093
Fuertes MA
Navarro-Ranninger C
P304
P356
10.1016/S1040-8428(00)00053-6
P577
2000-08-01T00:00:00Z